BlackRock Institutional Trust’s Atossa Therapeutics ATOS Stock Holding History

BlackRock Institutional Trust’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$10K	Hold	41	–	–	﹤0.01%	3793
2016 Q3	$16K	Hold	41	–	–	﹤0.01%	3824
2016 Q2	$31K	Hold	41	–	–	﹤0.01%	3790
2016 Q1	$38K	Hold	41	–	–	﹤0.01%	3809
2015 Q4	$36K	Hold	41	–	–	﹤0.01%	3835
2015 Q3	$85K	Hold	41	–	–	﹤0.01%	3750
2015 Q2	$125K	Buy	+41	New	+$164K	﹤0.01%	3695

Other funds holding ATOS

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

MFW

Mosaic Family Wealth St. Louis, Missouri $384M AUM 21.14% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Institutional Trust's ATOS Position: Q4 2016 in Review

BlackRock Institutional Trust held its Atossa Therapeutics (ATOS) position steady in Q4 2016 at 41 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #3793.

BlackRock Institutional Trust first reported a position in ATOS in Q2 2015 and has held it in 7 quarters since. The position peaked at $125K in Q2 2015. 10 funds tracked by Wall St. Rank hold ATOS as of Q4 2016.

BlackRock Institutional Trust held 41 shares of Atossa Therapeutics worth $10K as of Q4 2016.
BlackRock Institutional Trust left its Atossa Therapeutics share count unchanged in Q4 2016.
Atossa Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3793 holding.
BlackRock Institutional Trust first reported a position in Atossa Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Institutional Trust's Atossa Therapeutics position peaked at $125K in Q2 2015.
10 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.